Plasma big endothelin-1 levels at admission and future cardiovascular outcomes: A cohort study in patients with stable coronary artery disease

详细信息    查看全文

• 作者：Bing-Yang Zhou ; Yuan-Lin Guo ; Na-Qiong Wu ; Cheng-Gang Zhu ; Ying Gao ; Ping Qing ; Xiao-Lin Li ; Yao Wang ; Qian Dong ; Geng Liu ; Rui Xia Xu ; Chuan-Jue Cui ; Jing Sun ; Jian-Jun Li ; ^{lijianjun938@126.com}
• 关键词：Big endothelin-1 ; Stable coronary artery disease ; Cardiovascular outcomes
• 刊名：International Journal of Cardiology
• 出版年：2017
• 出版时间：1 March 2017
• 年：2017
• 卷：230
• 期：Complete
• 页码：76-79
• 全文大小：264 K
• 卷排序：230

文摘

Big endothelin-1 (ET-1) has been proposed as a novel prognostic indicator of acute coronary syndrome, while its predicting role of cardiovascular outcomes in patients with stable coronary artery disease (CAD) is unclear.Methods and resultsA total of 3154 consecutive patients with stable CAD were enrolled and followed up for 24 months. The outcomes included all-cause death, non-fatal myocardial infarction, stroke and unplanned revascularization (percutaneous coronary intervention and coronary artery bypass grafting). Baseline big ET-1 was measured using sandwich enzyme immunoassay method. Cox proportional hazard regression analysis and Kaplan–Meier analysis were used to evaluate the prognostic value of big ET-1 on cardiovascular outcomes. One hundred and eighty-nine (5.99%) events occurred during follow-up. Patients were divided into two groups: events group (n = 189) and non-events group (n = 2965). The results indicated that the events group had higher levels of big ET-1 compared to non-events group. Multivariable Cox proportional hazard regression analysis showed that big ET-1 was positively and statistically correlated with clinical outcomes (Hazard Ratio: 1.656, 95% confidence interval: 1.099–2.496, p = 0.016). Additionally, the Kaplan–Meier analysis revealed that patients with higher big ET-1 presented lower event-free survival (p = 0.016).ConclusionsThe present study firstly suggests that big ET-1 is an independent risk marker of cardiovascular outcomes in patients with stable CAD. And more studies are needed to confirm our findings.